PsyBio Therapeutics Corp. (PSYBF)
PSYBF Stock Price Chart
Explore PsyBio Therapeutics Corp. interactive price chart. Choose custom timeframes to analyze PSYBF price movements and trends.
PSYBF Company Profile
Discover essential business fundamentals and corporate details for PsyBio Therapeutics Corp. (PSYBF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
23 Apr 2021
Employees
4.00
Website
https://www.psybiolife.comCEO
Evan Mike Levine
Description
PsyBio Therapeutics Corp., a biotechnology company, focuses on the research, development, and commercialization of psychedelic-inspired regulated medicines for the treatment of mental health and other disorders in the United States. The company is headquartered in Coconut Creek, Florida.
PSYBF Financial Timeline
Browse a chronological timeline of PsyBio Therapeutics Corp. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 30 Jun 2023
EPS came in at -$0.00 .
Earnings released on 31 Mar 2023
EPS came in at -$0.01 .
Earnings released on 31 Dec 2022
EPS came in at -$0.02 .
Earnings released on 30 Sept 2022
EPS came in at -$0.01 .
Earnings released on 29 Aug 2022
EPS came in at -$0.01 falling short of the estimated -$0.01 by -34.95%.
Earnings released on 30 May 2022
EPS came in at -$0.01 surpassing the estimated -$0.02 by +29.65%.
Earnings released on 2 Mar 2022
Earnings released on 29 Nov 2021
EPS came in at -$0.02 falling short of the estimated -$0.01 by -100.00%.
Earnings released on 30 Aug 2021
EPS came in at -$0.04 falling short of the estimated -$0.01 by -300.00%.
Earnings released on 31 Dec 2020
EPS came in at -$0.00 .
PSYBF Stock Performance
Access detailed PSYBF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.